Atea Pharmaceuticals (AVIR) News Today $2.98 -0.01 (-0.33%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.98 0.00 (0.00%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stake Lessened by Almitas Capital LLCAlmitas Capital LLC trimmed its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 45.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 752,003 shares of the company's stock after selling 632,526 shMay 4 at 7:45 AM | marketbeat.comAtea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025May 1, 2025 | globenewswire.comJPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)JPMorgan Chase & Co. increased its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 329.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 409,259 shares of the company's stoApril 28, 2025 | marketbeat.comRBF Capital LLC Has $183,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)RBF Capital LLC cut its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 63.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 54,929 shares of the company's stock after selling 93,522 shares durApril 26, 2025 | marketbeat.comAtea Pharmaceuticals announces results from phase 2 study of bemnifosbuvirApril 24, 2025 | markets.businessinsider.comAtea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025April 23, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. decreased its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 3.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,666,854 shares of the company's stock afteApril 20, 2025 | marketbeat.comAtea Pharmaceuticals says strategic alternatives process ‘ongoing’April 17, 2025 | markets.businessinsider.comAtea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase ProgramApril 17, 2025 | globenewswire.comMorgan Stanley Remains a Hold on Atea Pharmaceuticals (AVIR)April 13, 2025 | markets.businessinsider.comMorgan Stanley Has Lowered Expectations for Atea Pharmaceuticals (NASDAQ:AVIR) Stock PriceMorgan Stanley lowered their target price on Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating on the stock in a research note on Friday.April 13, 2025 | marketbeat.comAtea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 studyApril 9, 2025 | msn.comADAR1 Capital Management LLC Invests $368,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)ADAR1 Capital Management LLC bought a new stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 110,000 shares of the company'sApril 9, 2025 | marketbeat.comAtea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusApril 9, 2025 | globenewswire.comDriver Notifies Atea Pharmaceuticals of Withdrawal of Notice of NominationMarch 31, 2025 | globenewswire.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder ValueMarch 30, 2025 | finanznachrichten.deAtea Pharmaceuticals takes steps to boost shareholder valueMarch 28, 2025 | investing.comAtea Pharmaceuticals cuts workforce by ~25% in Q1March 27, 2025 | msn.comAtea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder ValueMarch 26, 2025 | globenewswire.comThe Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of DirectorsMarch 26, 2025 | finance.yahoo.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Issues Statement Regarding Director NominationsMarch 22, 2025 | finanznachrichten.deAtea Pharmaceuticals Issues Statement Regarding Director NominationsMarch 21, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (AVIR): A Bull Case TheoryMarch 21, 2025 | insidermonkey.comAtea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025March 19, 2025 | globenewswire.comWhat is William Blair's Forecast for AVIR Q1 Earnings?Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Atea Pharmaceuticals in a report issued on Friday, March 7th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.40) foMarch 10, 2025 | marketbeat.comAtea Pharmaceuticals Reports Successful FDA Meeting and Plans Phase 3 Program for Hepatitis C TreatmentMarch 8, 2025 | nasdaq.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comAtea Pharmaceuticals (NASDAQ:AVIR) Receives "Outperform" Rating from William BlairWilliam Blair reissued an "outperform" rating on shares of Atea Pharmaceuticals in a research report on Friday.March 8, 2025 | marketbeat.comBML Capital Management LLC Has $25.49 Million Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)BML Capital Management LLC lifted its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 14.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,608,312 shares of the company's sMarch 8, 2025 | marketbeat.comAtea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting EffortsMarch 8, 2025 | tipranks.comAtea Pharmaceuticals’ Promising Earnings Call HighlightsMarch 7, 2025 | tipranks.comAtea Pharmaceuticals (NASDAQ:AVIR) Posts Quarterly Earnings ResultsAtea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05).March 7, 2025 | marketbeat.comAtea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)March 6, 2025 | markets.businessinsider.comAtea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 6, 2025 | globenewswire.comAtea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on ThursdayAtea Pharmaceuticals (NASDAQ:AVIR) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.March 1, 2025 | marketbeat.comAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025February 27, 2025 | globenewswire.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of DirectorsFebruary 24, 2025 | finanznachrichten.deAtea Pharmaceuticals Appoints Arthur S. Kirsch to Board of DirectorsFebruary 24, 2025 | globenewswire.comAtea Pharmaceuticals (AVIR) Expected to Announce Earnings on WednesdayAtea Pharmaceuticals (NASDAQ:AVIR) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comPeapod Lane Capital LLC Purchases New Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Peapod Lane Capital LLC acquired a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 328,581 shares of the company's stock, valueFebruary 13, 2025 | marketbeat.comShort Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Decreases By 12.9%Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 2,770,000 shares, a decline of 12.9% from the December 31st total of 3,180,000 shares. Approximately 3.7% of the company's stock are short sold. Based on an average daily volume of 309,000 shares, the days-to-cover ratio is currently 9.0 days.January 31, 2025 | marketbeat.comAtea Pharmaceuticals director Franklin Berger acquires $81,498 in stockJanuary 17, 2025 | msn.comBarclays PLC Has $593,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Barclays PLC grew its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 74.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 177,077 shares of the company's stock after acquiring an additional 75,624January 17, 2025 | marketbeat.comAtea Pharmaceuticals to highlight 2025 strategic prioritiesJanuary 14, 2025 | markets.businessinsider.comAtea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13, 2025 | finance.yahoo.comAtea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest UpdateAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 3,180,000 shares, a growth of 21.8% from the November 30th total of 2,610,000 shares. Currently, 4.3% of the shares of the stock are short sold. Based on an average daily volume of 266,600 shares, the days-to-cover ratio is presently 11.9 days.December 29, 2024 | marketbeat.comConcerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review ProcessDecember 18, 2024 | businesswire.comAtea Pharmaceuticals Retains Financial Advisor to Explore Strategic PartnershipsDecember 16, 2024 | globenewswire.com Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address AVIR Media Mentions By Week AVIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVIR News Sentiment▼1.120.73▲Average Medical News Sentiment AVIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVIR Articles This Week▼32▲AVIR Articles Average Week Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies X4 Pharmaceuticals News Enliven Therapeutics News Collegium Pharmaceutical News Pharvaris News Spyre Therapeutics News Mineralys Therapeutics News Intellia Therapeutics News Nurix Therapeutics News Gyre Therapeutics News Arcus Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVIR) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVIR Stock Free AVIR Stock Alerts